Clinical Trials for Ovarian Cancer

A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with select advanced/metastatic solid tumors after standard therapy (melanoma, cSCC, Merkel cell, NSCLC, HNSCC, gastric/GEJ, RCC, HGSOC, TNBC) receive AZD6750, an investigational CD8-guided IL-2 designed to preferentially activate CD8+ T cells; a separate module enrolls NSCLC (including 1L PD-L1 ≥1%) to receive AZD6750 plus rilvegostomig, a bispecific PD-1/TIGIT antibody. Key exclusions include uncontrolled CNS disease, active autoimmune disease, prior severe I/O toxicities, and in the NSCLC module prior anti-TIGIT or targetable driver-positive 1L disease.

ClinicalTrials.gov ID: NCT07115043

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, measurable solid tumors (ECOG 0–1) eligible for biopsy, including FRα‑expressing cancers such as ovarian, receive the investigational FRα‑targeted topoisomerase‑I ADC AZD5335 (torvutatug samrotecan) as monotherapy or combined with bevacizumab, carboplatin (± bevacizumab), or PARP1‑selective inhibitors (saruparib or AZD9574). Aimed at patients who have exhausted standard options, with exclusions for uncontrolled CNS disease and significant comorbidities; early data suggest higher activity in FRα‑high tumors.

ClinicalTrials.gov ID: NCT05797168

A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent clear cell or endometrioid ovarian carcinoma, platinum‑resistant HGSOC (dose‑escalation only), or recurrent FIGO grade 1 endometrioid/clear cell endometrial carcinoma receive oral tuvusertib (ATR inhibitor) plus ZEN‑3694 (pan‑BET inhibitor), with biomarker‑driven expansion enrolling both ARID1A‑mutated and ARID1A‑wild‑type cohorts. Aims include defining RP2D and assessing safety and preliminary activity, with mandated biopsies to explore pharmacodynamic effects and ARID1A‑related response.

ClinicalTrials.gov ID: NCT05950464

A Prospective Randomized Trial of Acute Normovolemic Hemodilution (ANH) in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Adults with suspected or confirmed stage IIIC–IV epithelial ovarian, fallopian tube, or primary peritoneal cancer undergoing primary or interval cytoreductive laparotomy (BLOODS ≥2, Hgb ≥10 g/dL) are randomized to intraoperative acute normovolemic hemodilution (autologous whole-blood collection with crystalloid/colloid replacement and reinfusion) versus standard intraoperative care. The trial tests whether ANH reduces perioperative allogeneic red blood cell transfusion within 30 days.

ClinicalTrials.gov ID: NCT06290193

Phase I Clinical Trial of Autologous B7-H3 Chimeric Receptor (CAR) T Cells in Adults With Recurrent, Platinum Resistant Ovarian Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent, platinum-refractory or -resistant epithelial ovarian cancer (including carcinosarcoma), ECOG 0–2, receive autologous B7‑H3 (CD276)–targeted CAR T cells after lymphodepletion, administered either intraperitoneally for peritoneal-only disease or intravenously if extra-peritoneal or IP not feasible. Investigational therapy targets broadly overexpressed B7‑H3; trial assesses feasibility/safety with dose escalation and early response signals.

ClinicalTrials.gov ID: NCT06646627

A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with measurable high-grade serous ovarian, primary peritoneal, or fallopian tube cancer after 1–3 prior lines (platinum-sensitive and -resistant cohorts; ECOG 0–1), excluding significant ILD/pneumonitis and other key comorbidities. Investigational CDH6-targeting antibody-drug conjugate raludotatug deruxtecan (anti-CDH6–DXd topoisomerase I payload) is combined with either carboplatin, paclitaxel, or bevacizumab, with chemotherapy for up to six cycles and continued R-DXd until progression.

ClinicalTrials.gov ID: NCT06843447

Phase I Trial of CPI-0209 in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (ECOG 0–2) receive oral CPI-0209 (tulmimetostat), a dual EZH2/EZH1 inhibitor aiming to reverse epigenetic platinum resistance, combined with carboplatin followed by CPI-0209 maintenance. Prior bevacizumab or PARP inhibitor is allowed; excludes platinum-resistant disease and significant comorbidities.

ClinicalTrials.gov ID: NCT05942300

A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-Directed Antibody-Drug Conjugate, in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors—emphasizing platinum‑refractory/resistant ovarian cancer—who have exhausted standard therapy receive CUSP06 (AMT‑707), a cadherin‑6–targeted IgG1 antibody‑drug conjugate delivering an exatecan (topoisomerase‑I) payload, given IV every 21 days. Open‑label dose escalation with tumor‑specific expansions; key exclusions include prior topoisomerase‑I ADCs and active CNS disease.

ClinicalTrials.gov ID: NCT06234423

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (relapse ≤6 months after last platinum; ≤2 prior cytotoxic lines) receive carboplatin/paclitaxel plus oral defactinib, a reversible ATP-competitive FAK/Pyk2 inhibitor aimed at re-sensitizing to platinum. Primary aims are safety/tolerability and objective response by RECIST 1.1.

ClinicalTrials.gov ID: NCT03287271

Phase I Evaluation of Combination CLK/DYRK (Cirtuvivint) Inhibition With PARP Inhibition (Olaparib) in BRCA/HRD Platinum Resistant Ovarian Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with platinum-resistant high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer that is BRCA-mutated and/or HRD-positive, with prior PARP inhibitor exposure and ≤3 prior lines, receive olaparib plus cirtuvivint. Cirtuvivint is an oral CLK/DYRK inhibitor that modulates pre-mRNA splicing and downregulates Wnt-pathway gene expression; two intermittent dosing schedules are tested with continuous olaparib 300 mg BID.

ClinicalTrials.gov ID: NCT06856499